SEER Inquiry System - Question 20061046 Details

System Guide

Back to Search Results

SEER Inquiry System - Report

Produced: 10/19/2025 4:47 PM

Question 20061046

Export CSV Export PDF Print

Add to Report

Inquiry Details

References:

#1: SEER*Rx

#2: Abs & Coding Guide Hem Dis, 3

Question:

First Course Treatment--Hematopoietic, NOS: How are Decadron and Zometa coded when used in the treatment of multiple myeloma? See Discussion.

Discussion:

The 2004 SEER Program Manual instructions for coding hormone therapy do not provide any specific instructions for coding adrenocorticotrophic agents. Per Abstracting and Coding Guide for the Hematopoietic Diseases pg. 3, prednisone and decadron are coded as hormonal therapy (when given as part of a chemotherapy regimen). Does this mean that Decadron without chemo agents is not coded as treatment? In paging through the hematopoietic disease manual, one sees this instruction for other sites as well. Yet, for other diseases (e.g., Waldenstroms macroglobulinemia on page 18), prednisone is coded as hormone therapy (not necessarily as part of chemo regimen).

Answer:

Code the decadron as hormonal treatment. Do not code the zometa--it is an ancillary agent.

In the August 2006 update of SEER*Rx, a note was added to decadron and other hormonal agents that they can be used to control white cell proliferation in lymphoma and multiple myeloma.

In general, decadron is used more commonly for supportive care and as an antiemetic than as hormone therapy.

Cancer Site Category:

N/A

Data Item Category:

First course treatment

Other Category:

N/A

Year:

2006